Duloxetine (DLX) + Placebo (PLA)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Osteoarthritis Knee Pain
Conditions
Osteoarthritis Knee Pain
Trial Timeline
Jul 1, 2009 → May 1, 2010
NCT ID
NCT00945945About Duloxetine (DLX) + Placebo (PLA)
Duloxetine (DLX) + Placebo (PLA) is a phase 3 stage product being developed by Eli Lilly for Osteoarthritis Knee Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT00945945. Target conditions include Osteoarthritis Knee Pain.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00945945 | Phase 3 | Completed |
Competing Products
20 competing products in Osteoarthritis Knee Pain